{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:48:14Z","timestamp":1785890894357,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018532","name":"Major Scientific and Technological Innovation Project of Shandong Province","doi-asserted-by":"publisher","award":["2020CXGC010503"],"award-info":[{"award-number":["2020CXGC010503"]}],"id":[{"id":"10.13039\/501100018532","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470764"],"award-info":[{"award-number":["32470764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taishan Industry Leading Talent Project"},{"name":"National Natural Science Foundation of China for Young Scholar Project","award":["82404586"],"award-info":[{"award-number":["82404586"]}]},{"name":"Natural Science Foundation of Qingdao Municipality Project","award":["2444zrjj101jch"],"award-info":[{"award-number":["2444zrjj101jch"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overcoming sorafenib resistance remains a major challenge in liver cancer treatment. This study evaluates the novel compound Psammaplysene D, alone or combined with sorafenib, against liver cancer, focusing on overcoming resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The efficacy of Psammaplysene D, alone or with sorafenib, was assessed using liver cancer cell lines and xenograft mouse models, including sorafenib-resistant variants. The direct binding interaction between Psammaplysene D and FGFR4 was confirmed through molecular docking and Cellular Thermal Shift Assay (CETSA). Transcriptomic profiling (RNA-seq) identified key differentially expressed genes. Ferroptosis induction was evaluated using key markers, and functional roles were validated using genetic and pharmacological approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Psammaplysene D inhibited liver cancer growth in vitro and in vivo, alone or synergistically with sorafenib, and overcame sorafenib resistance in both models. Mechanistic investigations revealed that Psammaplysene D directly targets FGFR4, inducing ferroptosis. In sorafenib-resistant cells, Psammaplysene D downregulates CYP26A1 expression, elevating retinoic acid (RA) levels. FGFR4 inhibition triggered ferroptosis and reduced CYP26A1 expression, while accumulated RA drove ferroptosis in resistant cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, Psammaplysene D is a potent therapeutic agent for liver cancer, effective alone or combined with sorafenib, and overcomes resistance through direct targeting of FGFR4, initiating a cascade of CYP26A1 downregulation, RA accumulation, and ferroptosis induction-defining a novel FGFR4\/CYP26A1\/RA axis regulating ferroptosis in resistant liver cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03622-1","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:32:56Z","timestamp":1767702776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4\/CYP26A1-retinoic acid axis to drive ferroptosis"],"prefix":"10.1186","volume":"45","author":[{"given":"Ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"3","key":"3622_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3622_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3622_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3622_CR4","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3622_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2677","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma. JAMA Oncol. 2024. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2677.","journal-title":"JAMA Oncol"},{"issue":"20","key":"3622_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"4","key":"3622_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"key":"3622_CR8","doi-asserted-by":"crossref","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A: Mechanisms of drug resistance in HCC. Hepatology 2023.","DOI":"10.1097\/HEP.0000000000000237"},{"issue":"6","key":"3622_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jhep.2021.07.029","volume":"75","author":"RM Gadaleta","year":"2021","unstructured":"Gadaleta RM, Moschetta A. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver. J Hepatol. 2021;75(6):1440\u201351.","journal-title":"J Hepatol"},{"issue":"3","key":"3622_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/joim.13767","volume":"295","author":"X Li","year":"2024","unstructured":"Li X, Lu W, Kharitonenkov A, Luo Y. Targeting the FGF19\u2013FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. J Intern Med. 2024;295(3):292\u2013312.","journal-title":"J Intern Med"},{"issue":"18","key":"3622_CR11","doi-asserted-by":"publisher","first-page":"17707","DOI":"10.1074\/jbc.M411771200","volume":"280","author":"C Yu","year":"2005","unstructured":"Yu C, Wang F, Jin C, Huang X, McKeehan WL. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem. 2005;280(18):17707\u201314.","journal-title":"J Biol Chem"},{"issue":"6","key":"3622_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","volume":"13","author":"J Potthoff Matthew","year":"2011","unstructured":"Potthoff Matthew J, Boney-Montoya J, Choi M, He T, Sunny Nishanth E, Satapati S, et al. FGF15\/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1\u03b1 Pathway. Cell Metab. 2011;13(6):729\u201338.","journal-title":"Cell Metab"},{"issue":"6024","key":"3622_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331(6024):1621\u20134.","journal-title":"Science"},{"key":"3622_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115955","author":"C Guo","year":"2024","unstructured":"Guo C, Zhou N, Lu Y, Mu M, Li Z, Zhang X, et al. FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomed Pharmacother. 2024. https:\/\/doi.org\/10.1016\/j.biopha.2023.115955.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"3622_CR15","doi-asserted-by":"publisher","first-page":"13575","DOI":"10.18632\/oncotarget.6185","volume":"7","author":"H Zhao","year":"2016","unstructured":"Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3beta\/beta- catenin signaling cascade via FGFR4 activation. Oncotarget. 2016;7(12):13575\u201386.","journal-title":"Oncotarget"},{"issue":"10","key":"3622_CR16","doi-asserted-by":"publisher","first-page":"8445","DOI":"10.1021\/acs.jmedchem.4c00758","volume":"67","author":"H Oh","year":"2024","unstructured":"Oh H, Kim J, Jung SH, Ha TH, Ahn YG, Nam G, et al. Discovery of 2,6-naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma. J Med Chem. 2024;67(10):8445\u201359.","journal-title":"J Med Chem"},{"key":"3622_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0478-9","author":"L Gao","year":"2017","unstructured":"Gao L, Wang X, Tang Y, Huang S, Hu C-AA, Teng Y. FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017. https:\/\/doi.org\/10.1186\/s13046-016-0478-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"3622_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2413-4","author":"L Ji","year":"2020","unstructured":"Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, et al. MiR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis. 2020. https:\/\/doi.org\/10.1038\/s41419-020-2413-4.","journal-title":"Cell Death Dis"},{"issue":"11","key":"3622_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1021\/np0703646","volume":"70","author":"MS Buchanan","year":"2007","unstructured":"Buchanan MS, Carroll AR, Addepalli R, Avery VM, Hooper JN, Quinn RJ. Psammaplysenes C and D, cytotoxic alkaloids from Psammoclemma sp. J Nat Prod. 2007;70(11):1827\u20139.","journal-title":"J Nat Prod"},{"issue":"17","key":"3622_CR20","doi-asserted-by":"publisher","first-page":"24027","DOI":"10.18632\/oncotarget.8210","volume":"7","author":"C Florean","year":"2016","unstructured":"Florean C, Schnekenburger M, Lee JY, Kim KR, Mazumder A, Song S, et al. Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. Oncotarget. 2016;7(17):24027\u201349.","journal-title":"Oncotarget"},{"issue":"4","key":"3622_CR21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/md13041621","volume":"13","author":"L Shaala","year":"2015","unstructured":"Shaala L, Youssef D, Badr J, Sulaiman M, Khedr A. Bioactive secondary metabolites from the Red Sea marine verongid sponge Suberea species. Mar Drugs. 2015;13(4):1621\u201331.","journal-title":"Mar Drugs"},{"issue":"5","key":"3622_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1021\/np300147d","volume":"75","author":"M Xu","year":"2012","unstructured":"Xu M, Davis RA, Feng Y, Sykes ML, Shelper T, Avery VM, et al. Ianthelliformisamines a-c, antibacterial bromotyrosine-derived metabolites from the marine sponge Suberea ianthelliformis. J Nat Prod. 2012;75(5):1001\u20135.","journal-title":"J Nat Prod"},{"key":"3622_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/md16050146","author":"A El-Demerdash","year":"2018","unstructured":"El-Demerdash A, Moriou C, Toullec J, Besson M, Soulet S, Schmitt N, et al. Bioactive bromotyrosine-derived alkaloids from the Polynesian sponge Suberea ianthelliformis. Mar Drugs. 2018. https:\/\/doi.org\/10.3390\/md16050146.","journal-title":"Mar Drugs"},{"key":"3622_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1452","author":"W Guo","year":"2023","unstructured":"Guo W, Li S, Qian Y, Li L, Wang F, Tong Y, et al. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression. Clin Transl Med. 2023. https:\/\/doi.org\/10.1002\/ctm2.1452.","journal-title":"Clin Transl Med"},{"key":"3622_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216210","author":"H He","year":"2023","unstructured":"He H, Sugiyama A, Snyder NW, Teneche MG, Liu X, Maner-Smith KM, et al. Acyl-CoA thioesterase 12 suppresses YAP-mediated hepatocarcinogenesis by limiting glycerolipid biosynthesis. Cancer Lett. 2023. https:\/\/doi.org\/10.1016\/j.canlet.2023.216210.","journal-title":"Cancer Lett"},{"key":"3622_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713660","author":"Q Mei","year":"2023","unstructured":"Mei Q, Xu X, Gao D, Xu Y, Yang J. Inhibition of notch signaling enhances antitumor activity of histone deacetylase inhibitor LAQ824. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241713660.","journal-title":"Int J Mol Sci"},{"key":"3622_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02195-5","author":"Y Mo","year":"2024","unstructured":"Mo Y, Han Y, Chen Y, Fu C, Li Q, Liu Z, et al. ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis. Mol Cancer. 2024. https:\/\/doi.org\/10.1186\/s12943-024-02195-5.","journal-title":"Mol Cancer"},{"key":"3622_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03203-8","author":"J Guo","year":"2024","unstructured":"Guo J, Gu H, Yin S, Yang J, Wang Q, Xu W, et al. Hepatocyte-derived Ig\u03ba promotes HCC progression by stabilizing electron transfer flavoprotein subunit \u03b1 to facilitate fatty acid \u03b2-oxidation. J Exp Clin Cancer Res. 2024. https:\/\/doi.org\/10.1186\/s13046-024-03203-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3622_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114996","volume":"43","author":"H Lu","year":"2024","unstructured":"Lu H, Liu H, Yan R, Ma W, Liu H, Liu R, et al. Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC. Cell Rep. 2024;43(12):114996.","journal-title":"Cell Rep"},{"key":"3622_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189310","author":"W Zhang","year":"2025","unstructured":"Zhang W, Hong X, Xiao Y, Wang H, Zeng X. Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189310.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"6","key":"3622_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2025.119989","volume":"1872","author":"Y Su","year":"2025","unstructured":"Su Y, Liu X, Wang D, Li G, Mi X, Zhang Y, et al. Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. Biochimica et Biophysica Acta (BBA). 2025;1872(6):119989.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"3622_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41419-025-07558-4","volume":"16","author":"Z Feng","year":"2025","unstructured":"Feng Z, Gao Y, Cai C, Tan J, Liu P, Chen Y, et al. CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R\/JAK2\/STAT3 positive feedback loop. Cell Death Dis. 2025;16(1):217.","journal-title":"Cell Death Dis"},{"issue":"13","key":"3622_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413682","volume":"12","author":"XY Wang","year":"2025","unstructured":"Wang XY, Liao Y, Wang RQ, Lu YT, Wang YZ, Xin YQ, et al. Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma. Adv Sci (Weinh). 2025;12(13):e2413682.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3622_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41419-025-07332-6","volume":"16","author":"J Lv","year":"2025","unstructured":"Lv J, Wang Y, Lv J, Zheng C, Zhang X, Wan L, et al. Pifithrin-mu sensitizes mTOR-activated liver cancer to sorafenib treatment. Cell Death Dis. 2025;16(1):42.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3622_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-025-10008-8","volume":"41","author":"H Xu","year":"2025","unstructured":"Xu H, Zheng S, Zhang Q, Xu Y, Zhang H, Hu T, et al. CUL1-neddylation contributes to K29-linked ubiquitination on p27 for autophagic degradation in sorafenib-resistant liver cancer. Cell Biol Toxicol. 2025;41(1):61.","journal-title":"Cell Biol Toxicol"},{"key":"3622_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.633453","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang C, Li J, Zhu J, Zhao C, Xu H. Novel regulatory factors and small-molecule inhibitors of FGFR4 in cancer. Front Pharmacol. 2021;12:633453.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3622_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","volume":"17","author":"P Zhang","year":"2024","unstructured":"Zhang P, Yue L, Leng Q, Chang C, Gan C, Ye T, et al. Targeting FGFR for cancer therapy. J Hematol Oncol. 2024;17(1):39.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3622_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40618-024-02408-0","volume":"48","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Hu B, Zhu D, Li X, Chen D, Wu N, et al. Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19\/FGFR4\/PRL. J Endocrinol Invest. 2025;48(1):67\u201380.","journal-title":"J Endocrinol Invest"},{"key":"3622_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151601","author":"L Chia","year":"2023","unstructured":"Chia L, Wang B, Kim J-H, Luo LZ, Shuai S, Herrera I, et al. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI151601.","journal-title":"J Clin Invest"},{"key":"3622_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105673","author":"W Nie","year":"2022","unstructured":"Nie W, Lu Y, Pan C, Gao J, Luo M, Du J, et al. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors. Bioorg Chem. 2022. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105673.","journal-title":"Bioorg Chem"},{"issue":"20","key":"3622_CR41","doi-asserted-by":"publisher","first-page":"11484","DOI":"10.1021\/acs.jmedchem.0c00044","volume":"63","author":"R Rezende Miranda","year":"2020","unstructured":"Rezende Miranda R, Fu Y, Chen X, Perino J, Cao P, Carpten J, et al. Development of a potent and specific FGFR4 inhibitor for the treatment of hepatocellular carcinoma. J Med Chem. 2020;63(20):11484\u201397.","journal-title":"J Med Chem"},{"issue":"6","key":"3622_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25(6):424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3622_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2025.05.393","volume":"237","author":"N Noguchi","year":"2025","unstructured":"Noguchi N, Saito Y, Niki E. Lipid peroxidation, ferroptosis, and antioxidants. Free Radic Biol Med. 2025;237:228\u201338.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3622_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-020-00205-0","volume":"25","author":"PF Liu","year":"2020","unstructured":"Liu PF, Feng YT, Li HW, Chen X, Wang GS, Xu SY, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cell Mol Biol Lett. 2020;25(1):10.","journal-title":"Cell Mol Biol Lett"},{"key":"3622_CR45","doi-asserted-by":"crossref","unstructured":"Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, Vuckovic AM, Travain VB, Zaccarin M, Zennaro L et al: Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol 2020, 28.","DOI":"10.1016\/j.redox.2019.101328"},{"issue":"5","key":"3622_CR46","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1067\/mjd.2001.113715","volume":"45","author":"PM Petkovich","year":"2001","unstructured":"Petkovich PM. Retinoic acid metabolism. J Am Acad Dermatol. 2001;45(5):S136\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3622_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/ATVBAHA.119.313366","volume":"40","author":"MA Rogers","year":"2020","unstructured":"Rogers MA, Chen JC, Nallamshetty S, Pham T, Goto S, Muehlschlegel JD, et al. Retinoids repress human cardiovascular cell calcification with evidence for distinct selective retinoid modulator effects. Arterioscler Thromb Vasc. 2020;40(3):656\u201369.","journal-title":"Arterioscler Thromb Vasc"},{"key":"3622_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phytochem.2024.114121","volume":"223","author":"ZP Jiang","year":"2024","unstructured":"Jiang ZP, Su R, Chen MT, Li JY, Chen HY, Yang L, et al. Ent-eudesmane sesquiterpenoids with anti-neuroinflammatory activity from the marine-derived fungus Eutypella sp. F0219. Phytochemistry. 2024;223:114121.","journal-title":"Phytochemistry"},{"issue":"11","key":"3622_CR49","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1021\/acscentsci.4c01167","volume":"10","author":"F Guo","year":"2024","unstructured":"Guo F, Xiao F, Song H, Li X, Xiao Y, Qin Y, et al. An optimized marinopyrrole A derivative targets 6-phosphoglucosamine synthetase to inhibit methicillin-resistant Staphylococcus aureus. ACS Cent Sci. 2024;10(11):2090\u20138.","journal-title":"ACS Cent Sci"},{"issue":"18","key":"3622_CR50","doi-asserted-by":"publisher","first-page":"11970","DOI":"10.1021\/acs.jmedchem.2c00532","volume":"65","author":"YY Jiang","year":"2022","unstructured":"Jiang YY, Gao Y, Liu JY, Xu Y, Wei MY, Wang CY, et al. Design and characterization of a natural Arf-GEFs inhibitor prodrug CHNQD-01255 with potent anti-hepatocellular carcinoma efficacy in vivo. J Med Chem. 2022;65(18):11970\u201384.","journal-title":"J Med Chem"},{"issue":"25","key":"3622_CR51","doi-asserted-by":"publisher","first-page":"13747","DOI":"10.1039\/C8RA02052C","volume":"8","author":"J Xu","year":"2018","unstructured":"Xu J, Wang K, Wu J. A short and efficient total synthesis of the bromotyrosine-derived alkaloid psammaplysene A. RSC Adv. 2018;8(25):13747\u20139.","journal-title":"RSC Adv"},{"issue":"19","key":"3622_CR52","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154\u201360.","journal-title":"JAMA"},{"issue":"3","key":"3622_CR53","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00280-011-1753-2","volume":"69","author":"I Petrini","year":"2011","unstructured":"Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, et al. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;69(3):773\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3622_CR54","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cam4.3618","volume":"10","author":"E Oki","year":"2021","unstructured":"Oki E, Makiyama A, Miyamoto Y, Kotaka M, Kawanaka H, Miwa K, et al. Trifluridine\/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): a multicenter phase II trial. Cancer Med. 2021;10(2):454\u201361.","journal-title":"Cancer Med"},{"issue":"23","key":"3622_CR55","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1158\/1078-0432.CCR-13-3445","volume":"20","author":"HY Lim","year":"2014","unstructured":"Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86\u20139766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):5976\u201385.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"3622_CR56","doi-asserted-by":"publisher","first-page":"14809","DOI":"10.1021\/acs.jmedchem.2c01319","volume":"65","author":"F Yang","year":"2022","unstructured":"Yang F, Chen X, Song X, Ortega R, Lin X, Deng W, et al. Design, synthesis, and biological evaluation of 5-formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as new selective, potent, and reversible-covalent FGFR4 inhibitors. J Med Chem. 2022;65(21):14809\u201331.","journal-title":"J Med Chem"},{"issue":"1","key":"3622_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38(1):3\u201315.","journal-title":"Int J Mol Med"},{"key":"3622_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010031","author":"L Lang","year":"2019","unstructured":"Lang L, Teng Y. Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8010031.","journal-title":"Cells"},{"issue":"10","key":"3622_CR59","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/17512433.2021.1947246","volume":"14","author":"M Repetto","year":"2021","unstructured":"Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Selective FGFR\/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Rev Clin Pharmacol. 2021;14(10):1233\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3622_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115947","volume":"263","author":"X Chen","year":"2024","unstructured":"Chen X, Huang Y, Chen B, Liu H, Cai Y, Yang Y. Insight into the design of FGFR4 selective inhibitors in cancer therapy: prospects and challenges. Eur J Med Chem. 2024;263:115947.","journal-title":"Eur J Med Chem"},{"key":"3622_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02659-4","author":"YQ Yang","year":"2023","unstructured":"Yang YQ, Zhang YB, Cao JQ, Su ZJ, Li F, Zhang PG, et al. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. J Exp Clin Cancer Res. 2023. https:\/\/doi.org\/10.1186\/s13046-023-02659-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3622_CR62","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"CH Yi","year":"2021","unstructured":"Yi CH, Chen LR, Lin ZF, Liu L, Shao WQ, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;74(5):2544\u201360.","journal-title":"Hepatology"},{"key":"3622_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07588-y","author":"EG Sun","year":"2025","unstructured":"Sun EG, Choi JN, Park MR, Kim DH, Sung M, Shim HJ, et al. FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer. Cell Death Dis. 2025. https:\/\/doi.org\/10.1038\/s41419-025-07588-y.","journal-title":"Cell Death Dis"},{"key":"3622_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.10","author":"RC Turkington","year":"2014","unstructured":"Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, et al. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014. https:\/\/doi.org\/10.1038\/cddis.2014.10.","journal-title":"Cell Death Dis"},{"key":"3622_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1567994","author":"M Yao","year":"2025","unstructured":"Yao M, Liu Z, Zhao W, Song S, Huang X, Wang Y. Ferroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1567994.","journal-title":"Front Immunol"},{"key":"3622_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01022-y","author":"X Dong","year":"2025","unstructured":"Dong X, Yang T, Jin Z. Lactobacillus reuteri-derived \u03b3-amino butyric acid alleviates MPTP-induced Parkinson\u2019s disease through inhibiting ferroptosis via the AKT-GSK3\u03b2-GPX4 axis. NPJ Parkinsons Dis. 2025. https:\/\/doi.org\/10.1038\/s41531-025-01022-y.","journal-title":"NPJ Parkinsons Dis"},{"key":"3622_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101439","author":"S Xu","year":"2025","unstructured":"Xu S, Zhou Y, Wan M, Bi Y, Liu P, Li Z, et al. LncRNA POU3F3 promotes osteosarcoma progression through GPX4-modulated ferroptosis by interaction with IGF2BP2 to facilitate NRF2 mRNA stability. Genes Dis. 2025. https:\/\/doi.org\/10.1016\/j.gendis.2024.101439.","journal-title":"Genes Dis"},{"key":"3622_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jes.2024.04.001","volume":"155","author":"Y Xia","year":"2025","unstructured":"Xia Y, Yang Q, Zhang L, Chen K, Yu X, Li Y, et al. Blue light induced ferroptosis in retinal damage via iron overload-associated oxidative stress. J Environ Sci (China). 2025;155:221\u201334.","journal-title":"J Environ Sci (China)"},{"key":"3622_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00945-2","author":"Z Yang","year":"2025","unstructured":"Yang Z, Yin S, Yi Z, Li Y, Wu S, Xu P, et al. Erigoster B targeting DECR1 induces ferroptosis of breast cancer cells via promoting phosphatidylcholine\/arachidonic acid metabolism. NPJ Precis Oncol. 2025. https:\/\/doi.org\/10.1038\/s41698-025-00945-2.","journal-title":"NPJ Precis Oncol"},{"key":"3622_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2024.100970","author":"T Yang","year":"2025","unstructured":"Yang T, Liu Z, Fu Z, Zhang X, Cao Y, Liang Q, et al. Albumin nanoassembly bi-directionally manipulated ferroptosis in tumor and CD8+ T cells for triple-negative breast cancer therapy. Asian J Pharm Sci. 2025. https:\/\/doi.org\/10.1016\/j.ajps.2024.100970.","journal-title":"Asian J Pharm Sci"},{"issue":"2","key":"3622_CR71","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.apsb.2024.12.005","volume":"15","author":"Y Hou","year":"2025","unstructured":"Hou Y, Zhong B, Zhao L, Wang H, Zhu Y, Wang X, et al. A small molecule cryptotanshinone induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1\/2\/Iron\/PARP\/calcium pathway. Acta Pharm Sin B. 2025;15(2):991\u20131006.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"3622_CR72","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41418-022-00941-0","volume":"29","author":"J Chen","year":"2022","unstructured":"Chen J, Li X, Ge C, Min J, Wang F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ. 2022;29(3):467\u201380.","journal-title":"Cell Death Differ"},{"key":"3622_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0187-x","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020. https:\/\/doi.org\/10.1038\/s41392-020-0187-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"3622_CR74","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/cas.15378","volume":"113","author":"N Iseda","year":"2022","unstructured":"Iseda N, Itoh S, Toshida K, Tomiyama T, Morinaga A, Shimokawa M, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer Sci. 2022;113(7):2272\u201387.","journal-title":"Cancer Sci"},{"key":"3622_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176493","author":"F Huang","year":"2024","unstructured":"Huang F, Shi X, Hu M, Yan H, Li X, Ding Y, et al. Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway. Eur J Pharmacol. 2024. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176493.","journal-title":"Eur J Pharmacol"},{"key":"3622_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30217-7","author":"Y Zou","year":"2022","unstructured":"Zou Y, Zheng S, Xie X, Ye F, Hu X, Tian Z, et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-30217-7.","journal-title":"Nat Commun"},{"key":"3622_CR77","doi-asserted-by":"crossref","unstructured":"Lavudi K, Nuguri SM, Olverson Z, Dhanabalan AK, Patnaik S, Kokkanti RR: Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Frontiers in Cell and Developmental Biology 2023, 11.","DOI":"10.3389\/fcell.2023.1254612"},{"issue":"4","key":"3622_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/nu3040385","volume":"3","author":"M Clagett-Dame","year":"2011","unstructured":"Clagett-Dame M, Knutson D. Vitamin A in reproduction and development. Nutrients. 2011;3(4):385\u2013428.","journal-title":"Nutrients"},{"key":"3622_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107400","author":"N Isoherranen","year":"2019","unstructured":"Isoherranen N, Zhong G. Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases. Pharmacol Ther. 2019. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107400.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3622_CR80","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-nutr-072610-145127","volume":"31","author":"A Catharine Ross","year":"2011","unstructured":"Catharine Ross A, Zolfaghari R. Cytochrome P450s in the regulation of cellular retinoic acid metabolism. Annu Rev Nutr. 2011;31(1):65\u201387.","journal-title":"Annu Rev Nutr"},{"key":"3622_CR81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.preteyeres.2013.07.004","volume":"37","author":"S Kato","year":"2013","unstructured":"Kato S, Matsukawa T, Koriyama Y, Sugitani K, Ogai K. A molecular mechanism of optic nerve regeneration in fish: the retinoid signaling pathway. Prog Retin Eye Res. 2013;37:13\u201330.","journal-title":"Prog Retin Eye Res"},{"key":"3622_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1465","author":"W He","year":"2023","unstructured":"He W, Wang X, Chen M, Li C, Chen W, Pan L, et al. Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells. Clin Transl Med. 2023. https:\/\/doi.org\/10.1002\/ctm2.1465.","journal-title":"Clin Transl Med"},{"issue":"20","key":"3622_CR83","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1016\/j.bmc.2012.08.044","volume":"20","author":"MS Gomaa","year":"2012","unstructured":"Gomaa MS, Lim AST, Wilson Lau SC, Watts A-M, Illingworth NA, Bridgens CE, et al. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates. Bioorg Med Chem. 2012;20(20):6080\u20138.","journal-title":"Bioorg Med Chem"},{"key":"3622_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81678-7","author":"S Wang","year":"2021","unstructured":"Wang S, Feng R, Shi Y, Chen D, Weng H, Ding H, et al. Intracellular alpha-fetoprotein interferes with all-trans retinoic acid induced ATG7 expression and autophagy in hepatocellular carcinoma cells. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-81678-7.","journal-title":"Sci Rep"},{"issue":"6","key":"3622_CR85","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.gendis.2022.04.011","volume":"9","author":"Y Sun","year":"2022","unstructured":"Sun Y, He Y, Tong J, Liu D, Zhang H, He T, et al. All-trans retinoic acid inhibits the malignant behaviors of hepatocarcinoma cells by regulating ferroptosis. Genes Dis. 2022;9(6):1742\u201356.","journal-title":"Genes Dis"},{"issue":"5","key":"3622_CR86","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/cas.12633","volume":"106","author":"N Ishijima","year":"2015","unstructured":"Ishijima N, Kanki K, Shimizu H, Shiota G. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. Cancer Sci. 2015;106(5):567\u201375.","journal-title":"Cancer Sci"},{"key":"3622_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01194-1","author":"K Wang","year":"2023","unstructured":"Wang K, Qiu X, Zhang Z, Xu H, Tan Y, Su R, et al. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1. Cell Commun Signal. 2023. https:\/\/doi.org\/10.1186\/s12964-023-01194-1.","journal-title":"Cell Commun Signal"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03622-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03622-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03622-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:05:09Z","timestamp":1770649509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03622-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3622"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03622-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Experimentation Committee of the Medical College of Marine Biomedical Research Institute of Qingdao (E-MBPD-2020\u20131-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}